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E-mail address: inagaki@metab.kuhp.kyoto-u.ac.jpWe identiﬁed urate oxidase (UOX) as a target of SIRT5 by comparing mitochondrial proteins in livers
of SIRT5-overexpressing transgenic (SIRT5 Tg) and wild-type mice by using two-dimensional elec-
trophoresis. Acetylation levels of UOX in liver of SIRT5 Tg mice were approximately half of those
in wild-type mice, and UOX activity was signiﬁcantly increased. In vitro-synthesized UOX protein
was acetylated when incubated withmitochondria fromwild-type mice liver but the levels were less
when incubated with those from SIRT5 Tg mice liver. These results suggest that SIRT5 activates UOX
through deacetylation in mouse liver mitochondria.
Structured summary of protein interactions:
Uox physically interacts with Sirt5 by anti bait coimmunoprecipitation (View interaction)
Catalase, Hsp60 and Uox colocalize by cosedimentation through density gradient (View interaction)
Hsp60, Uox and Sirt5 colocalize by cosedimentation through density gradient (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction SIRT5 knock-out mice, respectively. CPS1 is a key enzyme in theIt is known that lifespan is prolonged by calorie restriction in
species ranging from yeast to mice [1–3]. Recently, a 20-year lon-
gitudinal study in monkeys revealed that calorie restriction sup-
pressed risk of development of age-associated disease involving
brain atrophy, neoplasia, cardiovascular disease, and glucoregula-
tory impairment, thereby diminishing the incidence of age-depen-
dent death [4]. It is also reported that disruption of SIR2, which is a
NAD+-dependent histone deacetylase in nucleus, abolishes lifespan
extension by calorie restriction in yeast [5]. Mammals have seven
SIR2 homologues in the SIRT family (SIRT1–7). Among them, SIRT1,
SIRT2, SIRT3, and SIRT5 have NAD+-dependent protein deacetylase
activity. [6]. It is thought that SIRTs recognize the decrease in en-
ergy levels of the cell by calorie restriction as an increase in
NAD+ content [7]. SIRT5 protein, a member of the SIRT family, is
known to locate in mitochondria [8–10], and has not only the
NAD+-dependent deacetylase activity but also NAD+-dependent
desuccinylase and demalonylase activities [6,11]. Recently, we
[12] and the Guarente group [13] found independently that car-
bamoyl phosphate synthase 1 (CPS1) is a SIRT5 substrate protein
by using SIRT5-overexpressing transgenic (SIRT5 Tg) mice andchemical Societies. Published by E
5-overexpressing transgenic;
abetes and Clinical Nutrition,
wahara-cho, Shogoin, Sakyo-
(N. Inagaki).urea cycle, which detoxiﬁes ammonia generated in liver as a by-
product of gluconeogenesis from amino acids during fasting and
starvation. Ammonia is ﬁnally converted to urea in liver and is ex-
creted from kidney. We demonstrate that SIRT5 mRNA levels are
increased and that CPS1 protein is deacetylated and activated by
SIRT5 during fasting in mouse liver [14]. SIRT5 also deacetylates
cytochrome c [10], but its role is still unknown.
Urate oxidase (UOX) is a crucial enzyme that catalyzes conver-
sion of urate to allantoin, which has higher water solubility than
urate, the last step of purine catabolism in most mammals [14] ex-
cept human and hominoid primates including chimpanzee, gorilla,
and orangutan, which lack UOX activity [15]. In the present study,
to clarify the novel function and physiological role of SIRT5 protein
in liver of mice, we attempted to identify a novel protein that is
deacetylated and regulated by SIRT5 using SIRT5 Tg mice. We dem-
onstrate here that SIRT5 may regulate purine catabolism through
deacetylation and activation of UOX protein.
2. Materials and methods
Animal experiments: The mice were housed in an air-controlled
(temperature 25 C) room with dark-light cycle (10; 14 h). Animal
care and procedures were approved by the Animal Care Committee
of Kyoto University. As both lines (#36, #38) of 8–12 week-old
SIRT5-overexpressing transgenic (SIRT5 Tg) mice showed similar
data, all experiments were performed using one line (#36) and
its littermate wild-type mice [12].lsevier B.V. All rights reserved.
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chondria particle-enriched 10 k fraction from liver was performed
as described previously [16]. Liver from mice was disrupted in iso-
tonic buffer (PBS containing 0.2 M mannitol, 0.07 M sucrose, and
1 mM EDTA) with potter homogenizer, followed by centrifugation
at 800g at 4 C for 10 min to obtain post-nuclear supernatant. Post-
nuclear supernatant was centrifuged at 10,000g at 4 C for 10 min
to obtain the mitochondria particle-enriched precipitate and post-
mitochondria supernatant. The precipitate was suspended with
isotonic buffer and the 10 k fraction was obtained. Post-mitochon-
dria supernatant was then ultracentrifuged at 100,000g at 4 C for
30 min, and cytosol was obtained as a supernatant.
Separation of 10 k fraction into puriﬁed mitochondria and per-
oxisomes: Self-generated density gradient method with OptiPrep
(COSMO BIO) was performed for separation of 10 k fractions. The
fraction was suspended in 6 ml 25 % OptiPrep containing 60 mM
Mops-NaOH buffer (pH7.4), 0.25 M sucrose, 1 mM EDTA, and 0.1
% (v/v) ethanol. The suspension was centrifuged at 180,000g at
4 C for 3 h in a ﬁxed-angle rotor. The fractions were collected from
the density gradient by 500 lL of each upward displacement.
Two-dimensional electrophoresis and identiﬁcation of protein:
the 10 k fraction was lysed with rehydration buffer (8 M urea, 2%
CHAPS, 50 mM DTT, 0.2% Bio-Lyte (BIO-RAD), 0.001% bromophenol
blue), and applied to ReadyStrip IPG Strip (BIO-RAD) and separated
by isoelectric focusing electrophoresis with a range pH 7 to pH 10
using PROTEAN IEF cell (BIO-RAD). The IPG Strip was then sub-
jected to SDS–polyacrylamide gel electrophoresis. The obtained
gel was immunoblotted using anti-acetylated lysine antibody (Cell
Signaling). The acetylated proteins were visualized and analyzed
using Las 4000 mini (FUJIFILM). The protein spot the intensity of
which was decreased in SIRT5 Tg mice compared to wild-type mice
was isolated from another two-dimensional electrophoresed gel
and treated with trypsin; the peptides obtained at the indicated
spot were analyzed using MALDI-TOF-MS (APRO Life Science Insti-
tute, Inc.).
Measurement of urate oxidase activity: 10 k fractions from liv-
ers of SIRT5 Tg and wild-type mice were used for determination of
urate oxidase. Urate oxidase activity was assayed as described by
Priest and Pitts [17]. Brieﬂy, the reaction was started by adding
the 10 k fraction to the assay mixture containing 50 mM sodium
borate buffer (pH 8.5) and 0.125 mM urate sodium salt at room
temperature, and the decrease in absorbance at 292 nm was mea-
sured. One unit of urate oxidase activity corresponded to degrada-
tion of 1 mmol of urate at room temperature.
Immunoprecipitation: Mitochondria lysed with PBS containing
1 % Triton X-100 were incubated with anti-acetylated lysine anti-
body for 16 h at 4 C. Protein G Sepharose (GE healthcare) resin
was then added and incubation was continued for 3 h. The resin
was washed ﬁve times with PBS containing 0.1 % Triton X-100
and boiled with SDS sample buffer (0.2 M Tris, 10% sucrose, 10%
SDS, 5 mM EDTA). The sample was analyzed by immunoblotting
with anti-UOX (Cell Signaling) or anti-acetylated lysine or anti-
myc (Santa Cruz) antibody.
In vitro synthesis of non-acetylated UOX and incubation with
mitochondria and/or cytosol: Non-acetylated and myc-tag fused
UOX protein was synthesized using PURESYSTEM classic II (Bio-
Comber). UOX-myc template DNA for PURESYSTEM classic II was
synthesized by PCR using primers ‘‘GAAATTAATACGACTCACTA-
TAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGTTTAACTTTA
AGAAGGAGATATACCAATGGCCCATTAC’’, ‘‘TATTCATTACAAGTCCTC
TTCAGAAATGAGCTTTTGCTCCAGCCTGGAAGGCAGCTTCC’’, and
UOX cDNA as a template. The obtained UOX-myc template DNA
was added to solution containing PURESYSTEM solution A, PURE-
SYSTEM solution B, 2 lg/ll puriﬁed liver mitochondria from SIRT5
Tg mice or wild-type mice, and/or 2 lg/ll mice liver cytosol, and
incubated for 1 h at 37 C. Obtained solutions were lysed with 1%Triton X-100 and immunoprecipitated using anti-myc antibody
and then analyzed by immunoblotting using anti-myc antibody
or anti-acetylated lysine antibody.3. Results
3.1. Identiﬁcation of UOX as a target of SIRT5 protein
We already established two SIRT5-overexpressing transgenic
(SIRT5 Tg) mice lines [10]. We hypothesize that deacetylation of
SIRT5 substrate proteins may be promoted in liver of SIRT5 Tg mice
compared to that in wild-type mice. To search for a novel substrate
protein of SIRT5, we performed two-dimensional electrophoresis
and immunoblotting using anti-acetylated lysine antibody. As
SIRT5 is expressed in mitochondria, mitochondria-enriched 10 k
fractions from livers of SIRT5 Tg and wild-type mice were prepared
and subjected to isoelectric focusing electrophoresis, and sepa-
rated by SDS–PAGE. The acetylated proteins were then observed
by immunoblotting with anti-acetylated lysine antibody. One of
the proteins with spots having decreased intensity in liver of SIRT5
Tg mice (Fig. 1A, indicated by arrows) was picked up from another
electrophoresed two-dimensional gels of 10 k fraction in wild-type
mice, treated with trypsin, and analyzed by MALDI-TOF-MS
(Fig. 1B). The protein was identiﬁed as urate oxidase (UOX) from
peptide sequences determined by mass spectrometry (Table 1).
3.2. UOX is located both in mitochondria and peroxisomes
In mice, localization of UOX is controversial; some reports dem-
onstrate that UOX is located in mitochondria [18,19] while others
ﬁnd localization in peroxisomes [20]. In fact, mitochondria-en-
riched 10 k fraction from liver of wild-type mice contains not only
mitochondria but also peroxisomes. Thus, to clarify subcellular dis-
tribution of UOX, we performed self-generated density gradient by
high-speed ultracentrifugation using OptiPrep to separate mito-
chondria from peroxisomes.
The 10 k fraction prepared from liver of wild-type mice was sus-
pended by 25% OptiPrep solution, and ultracentrifuged at 180,000g
at 4 C. Samples were collected from the obtained density gradient
by 500 lL of each upward displacement, and analyzed by immuno-
blotting using anti-hsp60 antibody as a mitochondrial marker,
anti-catalase antibody as a peroxisomes marker, anti-UOX anti-
body, and anti-SIRT5 antibody (Fig. 2A). Mitochondria were distrib-
uted mainly in the top fractions of the density gradient, while
peroxisomes were distributed mainly in the bottom fractions.
UOX was distributed in both the top and bottom fractions, suggest-
ing that UOX is located both in mitochondria and peroxisomes. To
ascertain localization of UOX, we collected the top and bottom
three fractions as the puriﬁed mitochondria and peroxisomes frac-
tions, respectively, and the puriﬁed fractions were subjected to
immunoblotting for hsp60, catalase, UOX, and SIRT5 (Fig. 2B).
The relative ratio of SIRT5 protein level in mitochondria and per-
oxisomes fractions was not signiﬁcantly different from that of
hsp60, suggesting that SIRT5 is localized only in mitochondria.
The relative ratio of UOX protein level in puriﬁed mitochondria
fraction was signiﬁcantly higher than that of contaminated cata-
lase in puriﬁed mitochondria fraction, indicating that UOX is lo-
cated both in peroxisomes and mitochondria.
3.3. UOX is deacetylated and activated in liver mitochondria of SIRT5
Tg mice
To conﬁrm the result of two-dimensional electrophoresis, 10 k
fractions from SIRT5 Tg and wild-type mice were lysed by Triton-
X 100 and immunoprecipitated using anti-UOX antibody. The
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Fig. 1. Identiﬁcation of the target protein of SIRT5. (A) Immunoblot analyses of two-dimensional electrophoresed gels of the mitochondria-enriched 10 k proteins prepared
from livers of SIRT5 Tg and wild-type mice. The acetylated proteins were detected by immunoblotting using anti-acetylated lysine antibody. The position of the mitochondrial
protein prepared fromwild-type liver identiﬁed by MALDI-TOF-MS is shown by arrow (left panel). The acetylation level is decreased at the corresponding position in SIRT5 Tg
liver (indicated by arrow, right panel). (B) MALDI-TOF-MS analysis. The mitochondrial protein prepared from wild-type liver indicated in (A) was analyzed using MALDI-TOF-
MS.
Table 1
Characterization by MALDI-TOF-MS of the target protein of SIRT5.
Measured peptide mass (Da) Corresponding UOX peptide sequence Start-end
1006.4720 NDEVEFVR 11–18
1175.5104 CFATQVYCK 188–196
1215.6823 EVATSVQLTLR 42–52
1376.6725 DVDFEAIWGAVR 203–214
1511.7885 AHVYVEEVPWKR 108–119
1532.7736 RDVDFEAIWGAVR 202–214
1771.8417 FAGPYDKGEYSPSVQK 221–236
1915.9163 DYLHGDNSDIIPTDTIK 56–72
2158.1344 MGLINKEEVLLPLDNPYGK 272–290
2372.1900 TTQSGFEGFLKDQFTTLPEVK 165–185
2549.1693 HVHAFIHTPTGTHFCEVEQMR 127–147
2682.2319 NIETFAMNICEHFLSSFNHVTR 86–107
Mass of peptides corresponding to a tryptic digest of UOX. The corresponding sequence and position
(number of amino acid residues) in the sequence are indicated.
4078 Y. Nakamura et al. / FEBS Letters 586 (2012) 4076–4081obtained precipitates were then analyzed by SDS–PAGE followed
by immunoblotting by anti-UOX and anti-acetylated lysine anti-
bodies (Fig. 3A). The expression levels of UOX were not signiﬁ-
cantly different in SIRT5 Tg and wild-type mice, but the
acetylation level of UOX in SIRT5 Tg mice was approximately half
of that in wild-type mice (Fig. 3B). Furthermore, activity of UOX
was measured using 10 k fraction from liver of SIRT5 Tg and
wild-type mice. UOX activity was signiﬁcantly increased 1.4-fold
in SIRT5 Tg mice compared to that in wild-type mice (Fig. 3C). To
investigate whether SIRT5 protein directly interacts with UOX pro-
tein, we performed co-immunoprecipitation assay (Fig. 3D); 10 k
fraction prepared from liver of wild-type mice was lysed by 1% Tri-ton X-100 and immunoprecipitated with or without anti-UOX anti-
body and Protein G Sepharose resin, and the resin were boiled with
SDS sample buffer. The obtained samples were immunoblotted
using anti-UOX antibody and anti-SIRT5 antibody. SIRT5 protein
precipitate was detected with the precipitation of UOX protein.
Therefore it indicates that SIRT5 protein directly interacts with
UOX protein.
3.4. UOX is acetylated and deacetylated in liver mitochondria
From the results above, it is likely that UOX protein is deacety-
lated by SIRT5. However, it remains unclear how UOX is acetylated
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Fig. 2. Determination of UOX subcellular localization. (A) Density gradient of 10 k fraction using OptiPrep. The 10 k fraction was divided into mitochondria and peroxisomes
by using self-generated density gradient. Hsp60 and catalase were used as control for mitochondria and peroxisomes, respectively. (B) UOX distribution in puriﬁed
mitochondria and peroxisomes. Puriﬁed mitochondria (PM) and peroxisomes (PP) indicated in Fig. 2A were collected and immunoblotted by using anti-hsp60 (mitochondria
marker), anti-catalase (peroxisomes marker), anti-UOX antibodies, and SIRT5 (left panel). Relative expression ratio of these proteins (PM/PM + PP and PP/PM + PP) are
calculated by LAS-4000 mini and shown in right panel (N = 3). Values are means ± SEM. ⁄P < 0.01.⁄⁄P < 0.05. N. S.: no signiﬁcant difference.
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Fig. 3. Deacetylation and activation of UOX in livers of SIRT5 Tg mice. (A) UOX deacetylation in livers of SIRT5 Tg mice. The 10 k fractions from livers of SIRT5 Tg (Tg) and
wild-type (WT) mice were immunoprecipitated with anti-UOX antibody, and then immunoblotted with anti-UOX antibody or anti-acetylated lysine antibody. The left two
panels show immunoblotting of total UOX protein and acetylated UOX protein in mitochondria. (B) Measurement of acetylation ratio of UOX from wild-type and SIRT5 Tg
mice. The ratio of acetylated UOX protein of SIRT5 Tg liver to that of wild-type liver was calculated from densitometry of immunoblotting (N = 3; right two panels). (C)
Activation of UOX activity in SIRT5 Tg liver. 10 k fractions of livers in SIRT5 Tg (N = 10) and wild-type (N = 10) mice were used to determine the UOX activities. (D) Interaction
between UOX and SIRT5. 10 k fraction was lysed by 1% Triton X-100 and immunoprecipitated with (+) or without () anti-UOX antibody. Then immunoblot was performed
using anti-UOX antibody or anti-acetylated lysine antibody. Values are means ± SEM. ⁄P < 0.01. ⁄⁄P < 0.05.
Y. Nakamura et al. / FEBS Letters 586 (2012) 4076–4081 4079in the cell at physiological condition. We then investigated to ﬁnd
the component of the cell in which UOX protein is acetylated. First,
to differentiate in vitro-synthesized UOX from endogenous UOX,
UOX protein to which myc-tag was fused at C-terminus (UOX-
myc) was synthesized in vitro (Fig. 4A). It was conﬁrmed that there
was no non-speciﬁc protein band in the UOX-myc synthetic solu-
tion by immunoblotting using anti-UOX antibody, and that the
synthesized UOX protein was not acetylated by immunoblotting
using anti-acetylated lysine antibody (Fig. 4A). Next, UOX-myc
protein was synthesized with puriﬁed mitochondria from SIRT5Tg mice or wild-type mice and with cytosol. After 1 h incubation,
obtained suspensions were lysed by 1% Triton X-100 and immuno-
precipitated by anti-myc antibody, followed by immunoblotting
using anti-myc or anti-acetylated lysine antibodies (Fig. 4B). Total
synthesized UOX-myc protein levels were similar in all samples.
However, UOX-myc protein was acetylated only when it was incu-
bated with mitochondria. Furthermore, acetylation levels of UOX
protein in the presence of mitochondria from SIRT5 Tg mice were
decreased compared to those in the presence of mitochondria from
wild-type mice. These results suggest that UOX protein is acety-
- +
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     lysine ab
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Fig. 4. Acetylation of UOX in mitochondria. (A) In vitro synthesis of non-acetylated UOX protein. Non-acetylated UOX-myc was synthesized by using PURESYSTEM classic II
with or without UOX-myc template. Synthesized UOX-myc was validated by immunoblotteing using anti-UOX and anti-acetylated lysine antibodies. (B) Incubation of
in vitro-synthesized UOX-myc with mitochondria. UOX-myc protein was synthesized with mice liver cytosol and/or puriﬁed mitochondria from SIRT5 Tg (Mt(Tg))mice or
wilt-type (Mt(WT)) mice, and obtained solutions were lysed and immunoprecipitated using anti-myc antibody, followed by immunoblotting using anti-myc antibody (total
UOC-myc) or anti-acetylated lysine antibody (acetylated UOX-myc). Mitochondrial endogenous SIRT5 and transgene derived SIRT5-FLAG are indicated in lower panel.
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the UOX protein.
4. Discussion
We already reported that SIRT5 mRNA expression level was sig-
niﬁcantly increased in liver of wild-type mice during fasting com-
pared to that during feeding ad libitum [12], and Guarente group
also reported SIRT5 was activated during fasting [13]. Therefore,
it is thought that liver of SIRT5-overexpressing transgenic (SIRT5
Tg) mice mimics that of fasting wild-type mice.
In the present study, we attempted to identify a novel mito-
chondrial protein as the substrate of SIRT5 since SIRT5 is expressed
in mitochondria. Mitochondria-enriched 10 k fraction from livers
of SIRT5 Tg mice and littermate wild-type mice were analyzed by
two-dimensional electrophoresis, immunoblotting using anti-acet-
ylated lysine antibody, and MALDI-TOF-MS. UOX protein was iden-
tiﬁed as a novel SIRT5 substrate. There are reports showing that
UOX protein locates in peroxisomes [20], but we found that UOX
protein locates not only in peroxisomes but also in mitochondria
using a density gradient method. In addition, our ﬁnding that
in vitro-synthesized UOX-myc protein was acetylated when it
was incubated with mitochondria strongly supports UOX localiza-
tion at mitochondria. Kim et al. reported that UOX has at least 10
potential acetylation sites at lysine residues and that the acetyla-
tion state differs during ad libitum feeding and fasting in liver
mitochondria [19], suggesting that lysine residue of UOX may be
deacetylaed by SIRT5 during fasting.
It has been reported that SIRT5 has not only NAD+-dependent
deacetylase activity but also NAD+-dependent desuccinylase and
demalonylase activities [6,11]. Acetylation levels of UOX protein
in SIRT5 Tg mice were clearly decreased compared to those in
wild-type mice. However, as anti-acetylated lysine antibodies
including the antibody we use here are not fully speciﬁc and also
recognize differently acylated lysines, the type of UOX acyl modiﬁ-
cation removed by SIRT5 remains to be conﬁrmed. Furthermore,
we could not determine the succinylation and malonylation levels
of UOX protein. Therefore, we cannot exclude the possibility that
desuccinylation and demalonylation of UOX protein are involved
in its activation.
In mice, knock-out of UOX gene leads to hyperuricemia and ur-
ate nephropathy and more than half of these mice die before
4 weeks of age [21]. Thus, UOX is a critical protein for survival inmice. Urate is generated in liver by purine body, which is derived
mainly from skeletal muscle, and serum urate levels are elevated
during fasting and starvation. In the present study, we demon-
strated that acetylation levels of UOX in liver of SIRT5 Tg mice were
approximately half of those in wild-type mice and that the UOX
activity was signiﬁcantly increased in liver of SIRT5 Tg mice com-
pared to that in wild-type mice. Considered together, our results
indicate that mRNA levels of SIRT5 are increased and that UOX pro-
tein is deacetylated and activated by SIRT5 during fasting. As we
[12] and the Guarente group [13] have reported, SIRT5 regulates
the urea cycle by deacetylation and activation of CPS1. SIRT5 has
an important role in nitrogen metabolism at fasting and starvation
state in mitochondria as both urate and urea are products of nitro-
gen metabolism from nucleic acid and amino acid, respectively.
To determine the cellular compartment where UOX is acety-
lated, we incubated in vitro-synthesized, non-acetylated UOX with
mitochondria. UOX protein was not acetylated in the presence of
cytosol but it was acetylated in the presence of mitochondria. In
addition, UOX acetylation levels were lower when incubated with
liver mitochondria of SIRT5 Tg mice in comparison with wild-type
mice. These results demonstrate that the lysine residue of UOX
protein is acetylated in mitochondria in physiological conditions
and that there is an acetylation–deacetylation cycle in
mitochondria.
In human, the UOX gene is absent. However, recombinant UOX
protein is used in treatment as an anti-hyperuricemia agent in tu-
mor lysis syndrome [22–24]. Clarifying the regulatory mechanism
of UOX activation by SIRT5 should be useful to develop a more
effective agent.
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